# Niclosamide for Mild to Moderate COVID-19

> **NCT04399356** · PHASE2 · COMPLETED · sponsor: **Tufts Medical Center** · enrollment: 73 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Niclosamide
- **DRUG:** Placebo
- **OTHER:** Telehealth monitoring

## Key facts

- **NCT ID:** NCT04399356
- **Lead sponsor:** Tufts Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-01
- **Primary completion:** 2021-04-20
- **Final completion:** 2021-08-19
- **Target enrollment:** 73 (ACTUAL)
- **Last updated:** 2022-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04399356

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04399356, "Niclosamide for Mild to Moderate COVID-19". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04399356. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*